Case Report: When access is limited: using CYP3A4 inhibition to maintain clinical benefit from elexacaftor/tezacaftor/ivacaftor.

Front Pharmacol · 2026 · PMC13388172 · PMID 42488561

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

It is worth considering that this isolated case has many limitations when conferring effects more widely, with inter-individual variability likely to be significant from a drug metabolism, drug-tolerance and individual dose adjustment perspectives.

also in 774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.